Frontiers in Immunology (May 2022)

Annexin-A1 Tripeptide Attenuates Surgery-Induced Neuroinflammation and Memory Deficits Through Regulation the NLRP3 Inflammasome

  • Zhiquan Zhang,
  • Qing Ma,
  • Ravikanth Velagapudi,
  • William E. Barclay,
  • Ramona M. Rodriguiz,
  • William C. Wetsel,
  • William C. Wetsel,
  • William C. Wetsel,
  • Ting Yang,
  • Mari L. Shinohara,
  • Mari L. Shinohara,
  • Niccolò Terrando,
  • Niccolò Terrando,
  • Niccolò Terrando

DOI
https://doi.org/10.3389/fimmu.2022.856254
Journal volume & issue
Vol. 13

Abstract

Read online

Neuroinflammation is a growing hallmark of perioperative neurocognitive disorders (PNDs), including delirium and longer-lasting cognitive deficits. We have developed a clinically relevant orthopedic mouse model to study the impact of a common surgical procedure on the vulnerable brain. The mechanism underlying PNDs remains unknown. Here we evaluated the impact of surgical trauma on the NLRP3 inflammasome signaling, including the expression of apoptosis-associated speck-like protein containing a CARD (ASC), caspase-1, and IL-1β in the hippocampus of C57BL6/J male mice, adult (3-months) and aged (>18-months). Surgery triggered ASC specks formation in CA1 hippocampal microglia, but without inducing significant morphological changes in NLRP3 and ASC knockout mice. Since no therapies are currently available to treat PNDs, we assessed the neuroprotective effects of a biomimetic peptide derived from the endogenous inflammation-ending molecule, Annexin-A1 (ANXA1). We found that this peptide (ANXA1sp) inhibited postoperative NLRP3 inflammasome activation and prevented microglial activation in the hippocampus, reducing PND-like memory deficits. Together our results reveal a previously under-recognized role of hippocampal ANXA1 and NLRP3 inflammasome dysregulation in triggering postoperative neuroinflammation, offering a new target for advancing treatment of PNDs through the resolution of inflammation.

Keywords